It’s been a few weeks since I’ve written about the impact that COVID-19 is having on people with MS. Since then, the picture has changed — not a lot, but enough for the MS International Federation to modify its recommendations for that illness, people with MS, and disease-modifying therapies (DMTs).
The treatment equation for COVID-19 and MS is complex because of the dynamic nature of the way this virus attacks the body. In some people, it appears to trigger a cytokine storm, where small proteins in the immune system overreact to an infection, and in addition to attacking the virus, attack and severely damage the lungs and other vital organs.
That kind of attack seems similar to the way an overactive immune system attacks the central nervous system in people with MS. So, would our hyperactive immune system offer a level of protection against COVID-19, or would it make things worse? Do our DMTs, some of which suppress our immune system, offer any protection, or do they make things worse?
The MSIF guidance
The federation stated that, in general, people with MS who are being treated with a DMT should remain on it. People who are being treated with a DMT who have COVID-19 symptoms should discuss therapy options with their neurologist.
According to the federation, Avonex, Rebif, Plegridy (interferon beta-1a); Betaferon and Extavia (interferon beta-1b); and Glatopa (glatiramer acetate) are unlikely to increase the severity of COVID-19. Some preliminary evidence suggests these DMTs may actually reduce the need for hospitalization after being infected with the virus.
Some evidence suggests that Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), Gilenya (fingolimod), and Mayzent (siponimod) do not increase the risk of COVID-19 symptoms becoming more severe than they otherwise would.
On the other hand, the guidance cautions that therapies targeting CD20 — Ocrevus (ocrelizumab) and Rituxan (rituximab) — may be linked to an increased chance of being admitted to the hospital or requiring intensive care treatment due to COVID-19.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?